表皮生长因子受体酪氨酸激酶抑制剂与非小细胞肺癌的临床研究现状

Current status of clinical research on EGFR-TKI and non-small cell lung cancer

表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)能显著改善EGFR激活突变的晚期非小细胞肺癌(NSCLC)患者的生存期。几乎所有EGFR突变的NSCLC肿瘤最终都获得了对EGFRTKIs的耐药性,而获得EGFR-TKIs耐药性是目前治疗EGFR突变的NSCLC面临的巨大挑战。近几年来,在EGFR-TKI药物的研究及NSCLC的治疗方面有了新的突破,该文就EGFR-TKI与NSCLC的相关临床研究及应用取得的进展进行阐述。

Epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） can significantly improve the survival rate of patients who suffered terminal non-small cell lung cancer （NSCLC） with EGFR activating mutations. Almost all NSCLS with EGFR mutations eventually acquire resistance to EGFR-TKIs, which is a huge challenge on effective treatments. In recent years, there have been new breakthroughs in the research of EGFR-TKI and the treatment of NSCLC. This article describes the recent progresses in the clinical research and application of EGFR-TKI and NSCLC.